Piper Jaffray Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $242.61 --0%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Piper Jaffray upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $25.00 (from $19.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $17.99 yesterday.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $17.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Hengan International Group (1044:HK) (HEGIY) PT Lowered to HK$24.70 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
